SF99 -

1. My opinion on the potential of apabetalone is based on knowledge of medical science (my profession). My suggestion as to why it's all so painfully slow is speculation.

2. My guess is that the ridiculously low SP is due to a combination of epigenetics being a new field to investors, a track record of painfully slow progress, serial over-optimistic forecasts by Don, poor management, and very poor PR. Have I missed anything else?